ABSTRACT
INTRODUCTION
Parvovirus B19 (PB19) is a small, single-stranded DNA virus that is commonly spread by respiratory secretions or from hand to mouth contact, but can also occasionally be transmitted from the mother to the fetus during pregnancy 1 . Approximately 50-75% of women of reproductive age have developed immunity to PB19 1 . Although pregnancy has been shown not to affect the natural history of the infection, seronegative pregnant women, once exposed to the virus, can transmit the infection to their fetus in approximately 17-33% of cases 1 .
Even though the majority of fetuses affected by PB19 do not show any sign and have a spontaneous resolution of the infection 2 , several complications such as miscarriage and stillbirth may occur. Furthermore, fetal PB19 infection is among the most common causes of non-immune fetal hydrops, which carries a high risk of perinatal mortality and morbidity 3 . Long-term sequelae of congenital PB19 infection, such as cardiomyopathy, hepatic failure and abnormal neurodevelopmental outcome, have been reported 4 . The pathophysiology of PB19-related fetal damage is mainly dependent on the occurrence of fetal anemia due to the direct suppression of erythroid precursors in the early stages of hematopoiesis, although impaired myocardial contractility and fetal thrombocytopenia may play a role in this scenario 4, 5 . Accurate identification and treatment of fetuses affected by congenital PB19 infection is fundamental in order to improve perinatal outcome. The large majority of affected fetuses are identified due to the presence of signs of fetal anemia such as increased peak systolic velocity in the middle cerebral artery, ascites, cardiomegaly or hydrops. Therefore, identification of women presenting seroconversion for PB19 is fundamental in order to arrange appropriate fetal surveillance 6 . Delivery of the fetus or treatment of fetal anemia by intrauterine blood transfusion (IUT) represents the mainstay in prenatal management of fetal PB19 infection 7 . Despite this, the true prevalence of abnormal perinatal outcome in fetuses affected by PB19 infection has still to be ascertained. Small sample size of the studies, with even smaller number of cases included, and differences in gestational age at infection, fetal status and type of prenatal management once the infection has been established do not allow extrapolation of objective evidence on the burden of the short-and long-term complications occurring in fetuses affected by PB19 infection.
The aim of this systematic review was to elucidate the outcome of fetuses affected by congenital PB19 infection, with or without signs of hydrops on ultrasound.
METHODS

Protocol, eligibility criteria, information sources and search
This review was performed according to an apriori-designed protocol recommended for systematic reviews and meta-analyses 8 . PubMed, EMBASE and CINAHL databases were searched electronically on 20 August 2016 with an update on 23 June 2017 utilizing combinations of the relevant medical subject heading (MeSH) terms, keywords and word variants for 'Parvovirus B19', 'Parvovirus infection', 'prenatal diagnosis', 'prenatal ultrasonography' and 'prenatal care' (Table S1 ).
The search and selection criteria were restricted to the English language. Reference lists of relevant articles and reviews were hand-searched for additional reports. PRISMA guidelines were followed 9 .
Study selection, data collection and data items
The incidence of the following outcomes in fetuses with congenital PB19 infection was explored: miscarriage, defined as fetal loss at < 20 weeks' gestation; intrauterine death (IUD), defined as fetal demise occurring at ≥ 20 weeks' gestation; neonatal death (NND), defined as death occurring up to 28 days postpartum; perinatal death (PND), defined as occurrence of IUD or NND; spontaneous resolution of hydrops or fetal anemia in fetuses with and those without hydrops, respectively, defined as absence of such signs on ultrasound at follow-up assessment in fetuses not undergoing IUT; rate of IUT performed; resolution of hydrops or anemia after IUT, defined as absence of ultrasound signs suggestive of hydrops or anemia at the follow-up scan after the procedure; fetal loss following IUT, defined as miscarriage (if the procedure was performed before 20 weeks' gestation) or IUD (if IUT was performed after 20 weeks' gestation); abnormal brain scan after birth, defined as the presence on postnatal imaging (ultrasound, computerized tomography or magnetic resonance imaging) of any cerebral lesion suggestive of direct damage to the brain from the virus, or indirect damage resulting from the response of the host to infection or from fetal anemia or hydrops induced by the virus 10 ; and abnormal neurodevelopmental outcome, defined as the occurrence of any neurological lesion associated with a direct effect of the virus on the brain or secondary to fetal anemia or hydrops caused by the infection 10 . Observed fetal outcomes were reported according to presence or absence of signs of hydrops on ultrasound. Furthermore, a subgroup analysis was performed of hydropic and non-hydropic fetuses affected at < 20 and ≥ 20 weeks of gestation. Only fetuses with PB19 infection confirmed by serological or virological analysis or fetuses with signs of hydrops on ultrasound whose mothers had confirmed PB19 infection were considered suitable for inclusion.
Only studies reporting on prenatal diagnosis of fetal PB19 infection were considered suitable for inclusion in the current systematic review; postnatal studies or studies from which cases diagnosed prenatally could not be extracted were excluded. Studies including only cases of fetal or neonatal death were also excluded. Only full-text articles were considered eligible for inclusion; case reports, conference abstracts and case series with fewer than three cases of fetal PB19 infection were also excluded in order to avoid publication bias. Studies published before 2000 were not included, as we considered that advances in prenatal imaging techniques and improvements in the diagnosis and definition of fetal anomalies make these less relevant.
Two authors (F.B., D.M.) reviewed all abstracts independently and agreement regarding potential relevance was reached by consensus. Full-text copies of those papers were obtained, and the same two reviewers extracted independently relevant data regarding study characteristics and pregnancy outcome. Inconsistencies were discussed and consensus reached by the reviewers or by discussion with a third author. If more than one study reported on the same cohort with identical endpoints, the report containing the most comprehensive information on the population was included to avoid overlapping populations.
Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) 11 . According to the NOS, each study is judged on three broad perspectives: selection of the study groups, comparability of the groups and ascertainment of the outcome of interest. Assessment of selection of a study includes evaluation of the representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure and demonstration that the outcome of interest was not present at the start of the study. Assessment of comparability of a study includes evaluation of the comparability of cohorts on the basis of the design or analysis. Finally, ascertainment of the outcome of interest includes evaluation of the type of assessment of the outcome of interest, and length and adequacy of follow-up 11 . According to the NOS, a study can be awarded a maximum of one star for each of three numbered items within the selection and outcome categories; a maximum of two stars can be given for comparability.
Statistical analysis
Overall, we evaluated the association between hydrops fetalis secondary to PB19 infection and 10 fetal clinical outcomes (miscarriage, PND, IUD, NND, need for IUT, fetal loss after transfusion, resolution after transfusion, abnormal brain imaging, abnormal neurodevelopment, spontaneous resolution of the infection).
Some of the included observational studies reported zero events in one or both the compared groups, and exposed and unexposed group sizes were frequently unbalanced. In these cases, the best performing methods to obtain pooled estimates are the Mantel-Haenszel odds ratio without zero-cell continuity corrections, logistic regression and an exact method 12, 13 . Mantel-Haenszel odds ratios cannot be computed in studies reporting zero events in both groups, but the exclusion of these may cause a relevant loss of information and the potential inflation of the magnitude of the pooled exposure effect 14 . Therefore, in order to retain all studies in the analysis, we performed all meta-analyses using individual-data random-effects logistic regression, with single study as the cluster unit. The pooled datasets with individual data were reconstructed using published 2 × 2 tables. When one of the overall pooled arms showed no events, we used exact logistic regression analysis. Furthermore, only studies providing data for each explored outcome for both fetuses with and those without hydrops were considered eligible for the computation of odds ratios (ORs) [12] [13] [14] [15] . The formal tests for funnel plot asymmetry cannot be used when the total number of publications included for each outcome is below 10 or the events are very few, because the power is too low to distinguish chance from real asymmetry 13 . Thus, we assessed publication bias graphically, through funnel plots, and formally, through Egger's regression asymmetry test 16 , only in four out of 11 meta-analyses. All analyses were performed using Stata version 13.1 (2013, Stata Corp., College Station, TX, USA).
RESULTS
General characteristics
Of the 896 articles identified through the search, 87 were assessed for their eligibility (Table S2 ) and 35 studies were eventually included in the systematic review ( Figure 1 and Table 1 ). These 35 studies included 611 fetuses affected by PB19 infection based on serological or virological confirmation or presence of signs of fetal anemia, such as hydrops, on ultrasound in fetuses with infected mothers 6, . The definition of fetal hydrops in each included study is reported in Table S3 .
Quality assessment of the included studies according to the NOS is presented in Table 2 . Most of the included studies had an overall good score regarding selection and comparability of the study groups, and ascertainment of the outcome of interest. The main weaknesses of the studies were their retrospective design, small sample size, and heterogeneity in outcome definition, gestational age at assessment and type of prenatal management. Furthermore, not all the included studies were matched case-control series, thus making it possible for the robustness of the results to be affected by other cofactors.
Synthesis of results
The risk of miscarriage was higher in hydropic (pooled proportion (PP), 27.2%; 95% CI, 12. 24 Hartge (2015) 25 Kyeong (2015) 26 Yamada (2015) 27 Macè (2014) 28 Yoshida (2013) 29 Puccetti (2012) 30 Weiffenbach (2012) 31 De Jong (2012) 32 Santo (2011) 33 Chauvet (2011) 34 Fukushima (2011) 35 Enders (2010 45 Nunoue (2002) 46 Kailasam (2001) 47 Ismail (2001) 48 Suchet (2000) 49 Heinonen (2000) 50 Only first author is given for each study. A study can be awarded a maximum of one star for each of three numbered items within selection and outcome categories. A maximum of two stars can be given for comparability.
0.2-8.1%) and 3.0% (95% CI, 0.6-6.9%), respectively (Table 4) . In fetuses affected by hydrops, spontaneous resolution of the infection, defined as disappearance of signs of hydrops on follow-up ultrasound without the need for IUT, occurred in 5.2% (95% CI, 2.5-8.8%) of cases, whereas in the group of fetuses not affected by hydrops, spontaneous resolution of the infection, defined as absence of signs of fetal anemia on follow-up ultrasound, occurred in 49.6% (95% CI, 20.7-78.6%) of cases (Table 4) .
IUT was performed in 78.7% (95% CI, 66.4-88.8%) of hydropic and in 29.6% (6.0-61.6%) of non-hydropic fetuses affected by congenital PB19 infection and resolution of the infection after IUT occurred in 55 (Tables 3 and 4) .
Assessment of abnormal brain imaging and neurodevelopmental outcome was affected by the small number of included cases, which precluded a comprehensive assessment of the risk of such outcomes in the study groups, and therefore results should be interpreted with caution. The prevalence of abnormal brain imaging was 9.8% (95% CI, 2.5-21.0%) in fetuses affected and 0.0% (95% CI, 0.0-7.0%) in those not affected by hydrops, whilst the corresponding figures for abnormal neurodevelopmental outcome were 9.5% (95% CI, 2.6-20.2%) and 0.0% (95% CI, 0.0-7.5%).
Subgroup analysis according to gestational age at infection (< 20 and ≥ 20 weeks of gestation) was affected by the small number of studies and even smaller number of cases included, and thus results were reported only as pooled proportions (Tables S4 and S5 (Table S4) .
In non-hydropic fetuses, PND occurred in 2.9% (95% CI, 0.1-8.9%) of cases before and 6.7% (95% CI, 0.03-23.4%) after 20 weeks of gestation, while IUT was performed in 19.7% (95% CI, 0.1-59.4%) and 35.4% (95% CI, 8.7-68.5%) of cases, respectively (Table S5) . Fetal loss following IUT occurred in 46.2% (95% CI, 5.3-97.5%) of the cases before 20 weeks and in none after 20 weeks of gestation, whereas infection resolved spontaneously in 58.2% (95% CI, 3.8-99.9%) and in 33.9% (95% CI, 3.3-76.1%) of cases, respectively.
DISCUSSION
Main findings
The findings of this systematic review showed that presence of secondary hydrops is the main determinant in predicting perinatal outcome of fetuses affected by congenital PB19 infection. The risk of PND or IUD was higher in fetuses affected by hydrops, whereas there was no difference in the incidence of NND between the hydropic and non-hydropic groups. Spontaneous resolution of the infection occurred in about half of the cases not presenting with hydrops but in only about 5% of the cases with hydrops. Resolution of the infection after *When only one study could be included in meta-analysis, OR was computed from raw data of that study. †Computed using data from fetuses with infection before 20 weeks of gestation. IUT, intrauterine transfusion. Data from individual studies combined using proportion meta-analysis (random-effects model). *Computed using data from fetuses with infection before 20 weeks' gestation. IUT, intrauterine transfusion.
IUT was accomplished in about half of cases affected and in all cases not affected by hydrops, whilst IUD after IUT occurred in about 30% of hydropic and in 5% of non-hydropic fetuses.
Strengths and limitations
The small number of cases, heterogeneity of the populations (due to variability of inclusion criteria) and lack of standardized criteria for the antenatal management represent the major limitations of this systematic review. Assessment of the potential publication bias was also problematic because of the nature of the outcomes evaluated (outcome rates, with the left side limited to a value of zero), which limits the reliability of funnel plots, and because of the scarce number of individual studies, which strongly limits the reliability of formal tests. As not all included studies were case-control series reporting matched populations, it is possible that the presence and degree of association between some of the observed outcomes and the study populations might have been affected by several cofactors that were not balanced between cases affected and those not affected by hydrops, such as gestational age at occurrence of the infection, preterm birth and severity of the infection. One of the major limitations is represented by the populations analyzed in the original studies included in the review. Some of the included studies considered only fetuses affected by hydrops; although the analysis was stratified according to the presence of hydrops, it is possible that mainly cases showing severe degrees of hydrops were diagnosed on ultrasound, thus potentially overestimating the figures for the different adverse outcomes reported in this systematic review. On the other hand, the control group was mainly represented by fetuses showing signs of fetal anemia; in these fetuses, the prevalence of the explored outcomes is likely to be higher compared with that in affected but non-anemic cases.
Furthermore, we could not stratify the analysis according to the gestational age at infection as this information was reported only by a small proportion of the included studies. Finally, a comprehensive assessment of the risk of abnormal brain imaging and neurodevelopmental outcome in fetuses affected by PB19 infection was biased by the small number of cases and by heterogeneity in clinical assessment, neurodevelopmental tool used, time of follow-up and gestational age at birth. Despite these limitations, the present review represents the most comprehensive published estimate of fetal outcomes associated with congenital PB19 infection.
Implications for clinical practice
Although the outcome of fetuses affected by PB19 infection has been generally reported to be good, several complications such as miscarriage, IUD and hydrops can potentially occur 51 . Identification of the maternal serological status is the first step in stratifying the risk of fetal infection. If the mother is immune, she can be reassured that she will not develop the infection and that exposure will not result in adverse consequences. On the other hand, appropriate follow-up of those mothers showing seroconversion due to PB19 is fundamental in order to identify fetuses with complications. The risk of vertical transmission of PB19 has been estimated to be around 25% 52 . However, the likelihood for fetal infection has been reported to be higher when seroconversion occurs before the 20 th week of gestation, during the hepatic stage of hematopoiesis in which red blood cells have a reduced half-life and are more vulnerable to anemia 52 . In this scenario, a closer follow-up may be reasonable. Although there is no randomized trial on the type and frequency of antenatal follow-up of fetuses at high risk, it seems reasonable to perform a weekly ultrasound assessment to rule out signs of fetal anemia or hydrops for at least 8-12 weeks after the diagnosis of fetal infection 2 . Abnormal peak systolic velocity in the middle cerebral artery is the primary imaging marker for fetal anemia and has been shown to have an overall good diagnostic accuracy in identifying anemic fetuses 53 . Other signs include cardiomegaly, hyperechogenic bowel, ascites, polyhydramnios, meconium peritonitis and placentomegaly 51 . The present systematic review shows that the main determinant of adverse perinatal outcome in fetuses affected by congenital PB19 infection is the presence of hydrops. Fetal hydrops may be the consequence of high output heart failure secondary to fetal anemia or myocarditis and to hypoalbuminemia induced by liver failure. On the other hand, fetuses not affected by hydrops have generally an excellent clinical outcome. The rate of spontaneous resolution of the infection without the need for IUT in fetuses without hydrops was about 50%, whereas in all cases that underwent IUT fetal anemia resolved after one transfusion; however, these findings should be interpreted with caution in view of the small number of cases included in the analysis.
Recently, several studies have suggested that fetuses affected by PB19 infection are at higher risk of neurodevelopmental delay 4, 54, 55 . In the present systematic review, the prevalence of abnormal brain imaging and neurodevelopmental outcome was 9.8% (95% CI, 2.5-21.0%), 9.5% (95% CI, 2.6-20.2%) in fetuses presenting with hydrops and 0% in those without, although the small number of included cases precluded adequate statistical power and thus these findings should be interpreted with caution. Furthermore, the time of follow-up and the type of neurodevelopmental assessment used were not consistent between the included studies.
The association between PB19 infection and abnormal brain imaging and function has not been explained yet. Severe fetal anemia may lead to hypoxic ischemic encephalopathy, which may partially explain the relatively high prevalence of neurodevelopmental delay in children affected by PB19 infection in utero. Furthermore, PB19 DNA has been detected in white matter multinucleated reactive microglial cells, suggesting direct damage by the virus to the brain. Finally, acute fetal anemia can lead to a hyperdynamic state, which may impair cerebral perfusion. However, it is possible that several comorbidities, such as prematurity and growth restriction, may be partially responsible for the relatively high prevalence of neurodevelopmental delay in children with congenital PB19 infection. The risk of abnormal brain findings and neurodevelopmental delay should be discussed with parents and appropriate imaging and clinical follow-up arranged after birth.
Large prospective studies sharing objective protocols of prenatal management and postnatal assessment are needed to elucidate the actual prevalence of neurodevelopmental disorders in fetuses affected by PB19 infection.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Search strategy for PubMed, EMBASE and CINAHL for systematic review and meta-analysis (Table S4) or without (Table S5 ) signs of hydrops on ultrasound, according to gestational age at infection
